UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-34705 ___________________________ Codexis, Inc. (Exact name of registrant as specified in its charter) ____________________ ...

Codexis, Inc. (NASDAQ:CDXS) Q2 2022 Earnings Conference Call August 4, 2022 4:30 PM ET Company Participants Brendan Strong - Argot Partners John Nicols - President and Chief Executive Officer Ross Taylor - Chief Financial Officer Stephen Dilly - Board Member Conference Call Participants Steven Mah - Cowen and Company Matthew Hewitt - Craig-Hallum Ramakanth Swayampakula - H.C. Wainwright Operator Welcome to the Codexis Second Quarter 2022 Earnings Conference Call. At this time, all participants are in a list ...

CODEXIS® We engineer enzymes to improve health… of people and the planet Q2'2022 Results August 4, 2022 Forward Looking Statements 2 • These slides and any accompanying oral presentation contain forward-looking statements that involve risks and uncertainties. These statements relate to future events or our future financial or operational performance and involve known and unknown risks, uncertainties and other factors that could cause our actual results or levels of activity, performance or achievement to di ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-34705 ___________________________ Codexis, Inc. (Exact name of registrant as specified in its charter) _________________________ ...

CODEXIS® We engineer enzymes to improve health… of people and the planet Corporate Presentation May 2022 Forward Looking Statements 2 • These slides and any accompanying oral presentation contain forward-looking statements that involve risks and uncertainties. These statements relate to future events or our future financial or operational performance and involve known and unknown risks, uncertainties and other factors that could cause our actual results or levels of activity, performance or achievement to d ...

CODEXIS® We engineer enzymes to improve health… of people and the planet Q1'2022 Results May 5, 2022 Forward Looking Statements 2 • These slides and any accompanying oral presentation contain forward-looking statements that involve risks and uncertainties. These statements relate to future events or our future financial or operational performance and involve known and unknown risks, uncertainties and other factors that could cause our actual results or levels of activity, performance or achievement to diffe ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-34705 ___________________________ Codexis, Inc. (Exact name of registrant as specified in its charter) ________________________ ...

Codexis, Inc. (NASDAQ:CDXS) Q1 2022 Earnings Conference Call May 5, 2022 4:30 PM ET Company Participants John Nicols – President and Chief Executive Officer Ross Taylor – Senior Vice President and Chief Financial Officer Brendan Strong – Investor Relations, Argot Partners Conference Call Participants Steven Mah – Cowen Brandon Couillard – Jefferies Matthew Hewitt – Craig-Hallum Capital Group Evan Karev – Piper Sandler Operator Welcome to the Codexis First Quarter 2022, Earnings Conference Call. [Operator In ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2021 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File No.: 001-34705 Codexis, Inc. (Exact name of registrant as specified in its charter) Registrant's telephone number, including area code: (650) 42 ...

CODEXIS® We engineer enzymes to improve health… of people and the planet Q4 & FY'2021 Results February 24, 2022 Forward Looking Statements 2 • These slides and any accompanying oral presentation contain forward-looking statements that involve risks and uncertainties. These statements relate to future events or our future financial or operational performance and involve known and unknown risks, uncertainties and other factors that could cause our actual results or levels of activity, performance or achieveme ...